Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ivacaftor/lumacaftor

Ivacaftor/lumacaftor Reactions 1704, p215 - 2 Jun 2018 Osteopenia, height loss and non-traumatic compression fractures : case report A 19-year-old man developed osteopenia, height loss and non-traumatic compression fractures during treatment with ivacaftor/lumacaftor for cystic fibrosis. The man who had fat-soluble vitamin deficiency and osteopenia, was hospitalised for the treatment of a cystic fibrosis (CF) pulmonary exacerbation and a weight loss. He had been taking ivacaftor/lumacaftor [route and dosage not stated] for approximately 18 months for CF. On admission, a review of his growth chart showed a height loss of 8.5cm over the previous 5 months. One month before the admission, a dual energy X-ray absorption (DEXA) scan was significant for osteopenia. He was started on treatment for cystic fibrosis (CF) pulmonary exacerbation and was continued on ivacaftor/ lumacaftor. On further questioning, he reported a mild intermittent back pain over the previous six months. His musculoskeletal physical examination remained normal, except from the loss in height. A lumbar spine X-ray showed a superior end-plate fracture of L1 and a chest computed tomography scan showed the incidental finding of significant height loss of multiple mid-thoracic vertebrae. At follow-up, a total spine MRI revealed evidence of chronic compression fractures at the level http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Ivacaftor/lumacaftor

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018

Ivacaftor/lumacaftor

Abstract

Reactions 1704, p215 - 2 Jun 2018 Osteopenia, height loss and non-traumatic compression fractures : case report A 19-year-old man developed osteopenia, height loss and non-traumatic compression fractures during treatment with ivacaftor/lumacaftor for cystic fibrosis. The man who had fat-soluble vitamin deficiency and osteopenia, was hospitalised for the treatment of a cystic fibrosis (CF) pulmonary exacerbation and a weight loss. He had been taking ivacaftor/lumacaftor [route and dosage not...
Loading next page...
 
/lp/springer_journal/ivacaftor-lumacaftor-N7wQmaRlOp

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-018-46858-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p215 - 2 Jun 2018 Osteopenia, height loss and non-traumatic compression fractures : case report A 19-year-old man developed osteopenia, height loss and non-traumatic compression fractures during treatment with ivacaftor/lumacaftor for cystic fibrosis. The man who had fat-soluble vitamin deficiency and osteopenia, was hospitalised for the treatment of a cystic fibrosis (CF) pulmonary exacerbation and a weight loss. He had been taking ivacaftor/lumacaftor [route and dosage not stated] for approximately 18 months for CF. On admission, a review of his growth chart showed a height loss of 8.5cm over the previous 5 months. One month before the admission, a dual energy X-ray absorption (DEXA) scan was significant for osteopenia. He was started on treatment for cystic fibrosis (CF) pulmonary exacerbation and was continued on ivacaftor/ lumacaftor. On further questioning, he reported a mild intermittent back pain over the previous six months. His musculoskeletal physical examination remained normal, except from the loss in height. A lumbar spine X-ray showed a superior end-plate fracture of L1 and a chest computed tomography scan showed the incidental finding of significant height loss of multiple mid-thoracic vertebrae. At follow-up, a total spine MRI revealed evidence of chronic compression fractures at the level

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.